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Abstract: Multiple sclerosis (MS) is a chronic disease of the central nervous system that cul-
minates in the progression of physical and cognitive disability over time. Walking impairment 
is a ubiquitous feature of MS and a sentinel characteristic of the later or advanced stages of the 
disease. This paper presents a conceptual rationale along with empirical evidence for exercise 
training as a rehabilitation approach for managing walking impairment and improving walking 
function in persons with MS. Conceptually, MS is associated with a decrease in physical activity, 
which, in turn, can result in deconditioning across multiple domains of physiological functioning. 
The resulting deconditioning feeds back and further drives physical inactivity until a threshold is 
reached that likely initiates the progression of walking impairment in MS. Empirically, physical 
activity and exercise training have been associated with beneficial effects on walking function 
in persons with MS. This is based on cross-sectional, longitudinal, and experimental research 
that included diversity in the breadth of measures of walking, persons with MS, and exercise/
physical activity characteristics. Of particular importance, future researchers might consider 
examining the combinatory effects of exercise training plus pharmacological agents on walk-
ing mobility in MS. Collectively, exercise training and physical activity might hold significant 
potential for the management of progressive mobility disability in MS.
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Introduction
Multiple sclerosis (MS) is a chronic disabling disease of the central nervous system 
(CNS) that affects approximately 1 per 1000 persons in the United States.1 The majority 
of persons are diagnosed between the ages of 20 and 50 years, and women are more 
often affected than men.2 MS is more prevalent among people with northern European 
ancestry than those of African, Asian, and Hispanic ancestry.2 The most common course 
of MS is initially characterized by intermittent and recurrent episodes of multifocal 
inflammation in the CNS.3 Such inflammatory processes result in the demyelination 
and transection of axons in the brain, optic nerve, and spinal cord.4 The axonal damage 
results in conduction delay and block of electrical potentials along neuronal pathways.5 
Over the course of MS, there are further neurodegenerative processes that are presum-
ably characterized by insufficient support of nerve growth factors within the CNS.4,5 
The inflammatory and neurodegenerative processes and associated injury culminate 
in the progression of physical and cognitive disability in persons living with MS.
Walking impairment is one of the most ubiquitous features of MS and is a sentinel 
characteristic of the later or advanced stages of the disease. Importantly, walking 
impairment has been seen early in the MS disease course6 and represents a particular Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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concern of those living with this disease. The identification 
of therapeutic options for managing walking impairment and 
improving walking function in persons with MS therefore 
represents a topic of important scientific inquiry. This paper 
presents a conceptual rationale along with scientific evidence 
for exercise training as a rehabilitation approach for managing 
walking impairment and improving function in persons with 
MS. We have developed this rationale in four sections that 
offer important vantage points on the topic. The first section of 
the paper provides a background on the extent of impairment 
in walking among those with MS. The second section focuses 
on physiological deconditioning as a major contributing and 
alterable factor that underlies the progression of walking 
impairment over time in MS. This sets the background for 
the third section, which presents scientific evidence for exer-
cise training and physical activity as therapeutic modalities 
for managing walking impairment in MS. The final section 
provides an agenda for consideration by researchers with 
a particular focus on exercise training along with pharma-
cological agents as a combinatory approach for managing 
impairment of walking in MS. The over-arching goal of this 
paper is the provision of a scholarly resource for clinicians 
and practitioners who are interested in incorporating exercise 
training into the battery of therapeutic approaches for manag-
ing walking impairment in persons living with MS.
Walking impairments  
in MS
Walking impairment is one of the most life-limiting and 
common consequences of MS. The impairment in ambula-
tion among persons with MS has been documented using 
numerous clinical, performance, physiological, and kinematic 
measures. The expanded disability status scale (EDSS) is the 
most commonly used measure in clinical research involv-
ing persons with MS7 and is heavily weighted by walking 
ability, particularly in the mid-range of scores (4.0–7.0), as 
measured by the distance walked over 500 m.8 Natural history 
researchers have commonly defined benchmarks of disability 
in MS based on attainment of EDSS scores of 4.0 (ie, limited 
walking ability but able to walk more than 500 m without aid 
or rest) and 6.0 (ie, ability to walk with unilateral support no 
more than 100 m without rest);9,10 those EDSS scores reflect 
the onset and progression of significant limitations in walk-
ing, respectively. To that end, 50% of persons with MS will 
reach the two benchmarks of walking impairment within 
10–20 years of disease onset.9,10
Beyond the 500 m walk of the EDSS, researchers have 
often included other ambulatory performance measures for 
quantifying walking impairment in persons with MS; two of 
the most common are the timed 25-foot walk (T25FW)11 and 
6-minute walk (6MW)12 tests. The T25FW measures speed 
of walking, whereas the 6MW measures distance traveled 
as an estimate of walking endurance. Both measures have 
demonstrated reduced performance as a function of MS 
disease status. For example, one study reported that 6MW 
distance was reduced in persons with MS versus controls, 
and 6MW distance was reduced as a function of   increasing 
disability and self-reported ambulatory impairment (  Multiple 
Sclerosis Walking Scale-12) within those who had MS.12 
The existing cross-sectional research suggests that as 
MS-  related disability progresses, persons with MS have 
associated deteriorations in walking speed and endurance.
Other researchers have included physiological measures 
for quantifying walking impairment in persons with MS such 
as the energetic or oxygen (O2) cost of walking. The O2 cost 
of walking is measured in milliliters of O2 consumed per 
kilogram of bodyweight per meter travelled (mL⋅kg-1⋅m-1) 
and reflects the person’s capacity to supply requisite energy 
for walking (ie, energetic efficiency of walking). To date, 
researchers have reported that the O2 cost of walking on a 
treadmill is elevated in persons with MS who have moderate 
disability compared with controls.13 We recently reported that 
the O2 cost of walking was significantly higher in persons with 
MS who had mild disability compared with controls and that 
disability scores were strongly associated with the O2 cost 
of different speeds of treadmill and over-ground walking.14 
We further reported that O2 cost of walking was strongly 
correlated with Multiple Sclerosis Walking Scale-12 scores 
in persons with MS.15 This indicates that persons with MS 
require greater energy for ambulation and, by extension, 
walk less efficiently (ie, walking impairment); this ineffi-
ciency might reflect physiological or mechanical alterations 
in efficiency.
Some researchers have focused on spatial and temporal 
parameters of the gait cycle (ie, kinematic measures) for 
documenting walking impairment in MS. Such parameters 
describe alterations in the walking process itself and are 
important targets of gait rehabilitation. Researchers have 
reported that gait abnormalities such as reduced speed and 
stride length and prolonged double limb support time during 
walking are present even in persons with mild MS compared 
with matched controls.6 Other researchers have reported that 
speed, cadence, and stride length were dramatically reduced 
in a sample of persons with MS compared with matched 
controls, and the reduction was most pronounced in persons 
with MS who used a cane for assistance while walking.16 Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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This indicates that parameters of the walking cycle itself are 
affected in persons with MS.
Collectively, the research clearly demonstrates a prevalent 
and significant degree of walking impairment in persons with 
MS. Walking impairment itself can be measured using a 
breadth of tools including clinical rating scales, performance 
and physiological markers, and alterations in spatial and 
temporal gait parameters. One source of walking impairment 
in MS is obviously associated with neurological injury and 
damage itself and thus progresses as the disease progresses. 
There are other factors that are associated with walking 
impairments such as physiological deconditioning in persons 
without MS. This underscores the importance of considering 
these other, nondisease factors that might be associated with 
walking function in MS. Such consideration, in turn, sets the 
stage for examining exercise training and physical activity 
as influences of walking impairment in MS.
Physiological deconditioning, 
walking impairment,  
and MS
Physiological deconditioning might influence the onset and 
progression of walking impairment in persons with chronic 
diseases,17 including MS.18 Conceptually, MS is associated 
with a decrease in physical activity, which, in turn, can result 
in deconditioning across multiple domains of physiological 
functioning (eg, aerobic capacity, muscle strength, and 
balance). The resulting deconditioning feeds back and further 
drives physical inactivity in a cycle (Stage 1), until a threshold 
is reached that is likely to be associated with an impact on 
mobility. This then starts a cycle for the progression of walk-
ing impairment in MS (Stage 2), which might not entirely 
be linked with the burden of neurodegeneration in the CNS. 
This two-stage process is illustrated in Figure 1.
Empirically, there is strong evidence for general physical 
inactivity19 and physiological deconditioning18,20 in persons 
with MS. The physiological deconditioning manifests 
as reductions in aerobic capacity, muscle strength, and 
balance.20 There is initial evidence that physical inactiv-
ity and/or the disease itself are associated with reduced 
peak aerobic capacity21 as well as reduced isometric and 
voluntary force production, muscle cross-sectional area, 
type-I muscle fiber number, and biochemical function22,23 
in persons with MS. Moreover, parameters of physiological 
functioning (eg, aerobic capacity and muscle strength) are 
important influences of mobility disability in senescence,24,25 
MS,16,21 and other neurological conditions.26 The aforemen-
tioned conceptual model combined with empirical evidence 
support exercise training as an approach for attenuating the 
progression of walking impairment by increasing physical 
activity and improving physiological functioning in persons 
with MS. This is tantamount to preventing or disrupting the 
aforementioned cycle of inactivity and mobility impairment 
before or after its onset.
Importantly, there are other possible explanations for 
an effect of exercise training on walking impairment in 
MS. Exercise training might work via physiological func-
tioning independently or in combination with effects on 
Stage 1
Multiple
sclerosis
Physical
inactivity
Physiological
deconditioning
Stage 2
Multiple
sclerosis
Physical
inactivity
Physiological
deconditioning
Mobility 
disability
Figure 1 The two-stage cycle of physical inactivity, physiological deconditioning, and walking impairment in persons with MS.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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synaptogenesis27 and/or nerve growth factors.18 An additional 
possibility is that exercise training might have beneficial 
effects on cognition, fatigue, and mood as influences of 
walking impairment in MS.
Exercise training, walking 
impairment, and MS
Scientific evidence indicates that exercise training and 
physical activity might have beneficial effects on a num-
ber of outcomes (eg, fitness, mood, and quality of life), 
including walking impairment in MS. By definition, exer-
cise is one component of physical activity that is planned, 
structured, and repetitive; performed over an extended period 
(ie, exercise training); and often prescribed by a physician 
or exercise specialist with a specific external objective 
such as improved fitness or health.28 Physical activity, by 
comparison, is defined as any bodily movement produced 
by contraction of skeletal muscles and that increases energy 
expenditure above resting levels.28 This broadly defined 
behavior includes exercise along with leisure-time physical 
activity, sport, occupational work, transportation, and house-
hold chores. By definition, exercise and physical activity are 
inter-related, but not synonymous, and available research 
demonstrates that both might impact walking impairment 
and MS-related disability.
Exercise training and physical activity are promising 
behavior strategies for managing many of the consequences 
associated with MS. The benefits have been summarized 
in general literature reviews,18,20,29 a systematic Cochran 
review,30 and a meta-analysis.31 One meta-analysis indicated 
that physical activity, in the form of exercise training, was 
associated with improved quality of life and fatigue in persons 
with MS.31 Other benefits of physical activity in persons with 
MS include improved muscle strength, body composition, 
and cardiorespiratory, and fitness as well as management of 
symptoms such as anxiety and depression.18,20,29,30
Of central importance for this paper, we have focused on 
the relationships among physical activity, exercise training, 
and markers of walking impairment in persons with MS. One 
of our studies examined the association between physical 
activity and walking impairment in a validation of physical 
activity measures among persons with MS.32 Thirty persons 
with MS wore a pedometer and a single-axis accelerometer 
over a 7-day period, completed the Godin Leisure-Time Exer-
cise Questionnaire, and underwent a 7-day physical activity 
recall and an EDSS assessment for measuring mobility dis-
ability. Importantly, there were statistically significant and 
medium sized correlations between EDSS scores and physical 
activity as measured by total daily activity counts from the 
accelerometer (r = –0.37, P , 0.01) and total daily step counts 
from the pedometer (r = –0.34, P , 0.01). These results 
provide preliminary evidence of an association between 
objectively measured physical activity and mobility disability 
in a small sample of ambulatory persons with MS.
Another study examined the association between accel-
erometer activity counts as an objective measure of physical 
activity and scores from the Multiple Sclerosis Walking 
Scale-12.33 This scale is a 12-item patient-rated outcome 
for measuring the impact of MS on walking (ie, mobility 
disability) that has been validated and included in clinical 
trials involving persons with MS. The sample of persons with 
MS (N = 133) was recruited through support group meet-
ings of Midwestern chapters of the National MS Society. 
The participants completed the Multiple Sclerosis Walking 
Scale-12 along with other measures, including the EDSS, 
and wore a single-axis accelerometer over a 7-day period. 
There were statistically significant correlations between total 
daily activity counts from the accelerometry and Multiple 
Sclerosis Walking Scale-12 scores in the overall sample 
(r = –0.64, P , 0.01) and in the subsamples of persons 
with mild-to-moderate (EDSS scores of 1–4.5; r = –0.51, 
P , 0.01) and moderate-to-severe (EDSS scores of 5–8; 
r = –0.48, P , 0.01) MS-related disability. These results 
provide supplementary evidence of an association between 
objectively measured physical activity and mobility disability 
in MS, particularly among those with significant MS-related 
disability.
The next study involved a secondary analysis of data from 
an ongoing, longitudinal study of symptoms and physical 
activity34 and focused on the association between physical 
activity and walking impairment in a large cohort of persons 
with MS (N = 269).35 The participants wore a single-axis 
accelerometer over a 7-day period and completed the Godin 
Leisure-Time Exercise Questionnaire, International Physical 
Activity Questionnaire, Multiple Sclerosis Walking Scale-12, 
and Patient-Determined Disease Steps.   Bivariate correlation 
and confirmatory factor analyses indicated that (a) Godin 
  Leisure-Time Exercise Questionnaire and International Physi-
cal Activity Questionnaire scores were strongly correlated and 
loaded significantly on a physical activity factor, (b) Multiple 
Sclerosis Walking Scale-12 and Patient-Determined Disease 
Steps scores strongly correlated and loaded significantly 
on a walking mobility factor, and (c) there was a moderate 
and statistically significant association between the physical 
  activity and walking mobility factors (r = –0.40, P , 0.01). 
Such data further indicate that   physical activity is associated Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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with mobility disability but in a large sample of persons with 
MS using advanced statistical methodology.
The previously reviewed studies have been cross-
sectional and limit inferences about change. Using a panel 
design, we next examined physical activity as a predictor of 
disability progression in persons with MS over a 6-month 
period.36 Importantly, panel designs involve the collection 
of observations or data at more than one point in time using 
the same persons, and this design allows for studying the 
dynamics of relationship changes over time. Panel analy-
sis, in turn, is an appropriate analytic procedure for testing 
hypothetical relationships about the effects of changes in 
variables on one another over time. The sample (N = 269) 
of persons with MS completed the Godin Leisure-Time 
Exercise Questionnaire, International Physical Activ-
ity Questionnaire, Multiple Sclerosis Walking Scale-12, 
and Patient-Determined Disease Steps before and after a 
6-month observational period. The panel analysis indicated 
that baseline physical activity had a direct effect on walking 
impairment (path coefficient = −0.31), and change in physi-
cal activity across a 6-month period had a direct effect on 
residual change in progression of walking impairment (path 
coefficient = −0.16). This study was limited by the lack of 
performance measures of ambulation, but the findings pro-
vide preliminary support for a reduction in physical activity 
as a predictor of walking impairment over time in persons 
with MS. By extension, the delivery of an intervention that 
increases physical activity through exercise training or 
principles of behavior change could forestall, stabilize, or 
improve walking impairment in MS.
We have recently examined the overall effect of exercise 
training on walking mobility among persons with MS using 
meta-analytic procedures.37 This involved an extensive search 
for published exercise training studies. Studies were selected 
if they measured walking mobility, using instruments identi-
fied as acceptable walking mobility constructs and outcome 
measures for persons with neurological disorders (eg, 
EDSS, T25FW, 6MW, O2 cost of walking, Multiple Sclero-
sis Walking Scale-12, and temporal and spatial parameters 
from motion capture), before and after an intervention that 
included exercise training. We excluded published studies 
that only included physical therapy or exercise training as 
a small part of a physiotherapy program. This allowed for a 
focus on exercise training effects on walking outcomes. Of 
the 43 published papers we located and reviewed, only 22 
provided enough data to compute effect sizes expressed as 
Cohen’s d. We retrieved 66 effect sizes from the 22 publica-
tions, which included 609 MS participants, and the weighted 
mean effect size was g = 0.19 (95% confidence interval = 0.09, 
0.28). This effect size is obviously small by conventional 
standards. Nevertheless, the effect size might have clinical 
relevance when compared with the overall effectiveness of 
disease modifying agents for reducing disease progression 
and EDSS scores (d = 0.20).38 The cumulative evidence from 
the meta-analysis supports that exercise training is associated 
with a small, but potentially meaningful, improvement in 
walking mobility among persons with MS.
Overall, the accumulating evidence supports the argument 
that increased physical activity and exercise training will 
have beneficial effects on walking function in persons with 
MS. This is based on cross-sectional, longitudinal, and 
experimental research designs that included diversity in 
the breadth of measures of walking and persons with MS 
(eg, clinical MS course, disease duration, and disability 
status) and a compendium of interventions (ie, exercise 
training and physical activity level changes). This research 
serves as a platform that can be used to expand and broaden 
our application of exercise training and physical activity as 
a therapeutic approach for managing mobility   impairment 
in MS. This research further lays the groundwork for 
subsequent examinations of physiological functioning as a 
mechanism for improvements in walking impairment and 
the consideration of exercise training and pharmacological 
agents as a combinatory approach for addressing mobility 
impairment in MS.
Future research on exercise  
training and walking impairment  
in MS: four agenda items
As previously posited and illustrated in Figure 1, physiologi-
cal deconditioning often results from physical inactivity that 
is common in MS. Physiological deconditioning may prove 
to be an important and reversible contributor to mobility 
impairment, over and beyond the disease itself, in persons 
with MS.17,18 To that end, exercise training and behavior 
change interventions are primary approaches for increasing 
structured and lifestyle physical activity, respectively, and, 
in turn, improving physiological functioning and slowing, 
stopping, or reversing mobility disability in those with MS. 
To date, there have been few randomized controlled trials 
to test this mechanistic hypothesis. Indeed, this is an area of 
research that is still in infancy and that holds promise to pro-
vide clinicians and therapists with an evidence-based model 
that guides the integration of exercise training and behavior 
change interventions into regimens for managing the progres-
sion of walking dysfunction in MS. Yet, many elements still Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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to be understood include the optimal type or mode, intensity, 
frequency, duration, and maintenance of exercise training for 
optimizing physiological functioning and walking function 
in MS. One particular consideration is the optimal intensity 
of the exercise training stimulus. Indeed, exercise that is too 
intense might result in immune and stress hormone changes 
that are counter productive for beneficial effects on mobility 
outcomes and the MS disease course. We further note that 
too intense an exercise training stimulus might exacerbate 
and/or worsen MS-related fatigue. This is arguably one of the 
most impairing symptoms of MS. The worsening of fatigue 
might undermine long-term involvement in physical activity 
and/or exercise training.
Future research might consider examining the combina-
tory effects of exercise training plus pharmacological agents 
on walking mobility in MS. Perhaps the most obvious direc-
tion involves examining the combined, and perhaps syner-
gistic, effects of exercise training plus the 4-aminopyridine 
fampradine (Ampyra®) on walking outcomes. The rationale 
for fampridine, in particular, is based on demyelinated 
axons having abnormal potassium currents that manifest in 
conduction failure by decreasing the propagation of action 
potentials. The potassium channel blocker 4-aminopyridine 
or fampradine should improve nerve impulse conduction 
and affect a variety of outcomes. There is evidence that 
fampridine improves visual function, strength, ambulation, 
fatigue, and endurance in persons with MS.39–42 The most 
exciting evidence for beneficial effects is from a randomized, 
multicentre, double-blind, controlled Phase III trial of 301 
patients who were treated with either fampridine (10 mg 
twice daily; n = 229) or placebo (n = 72).43 The primary 
outcome was a responder analysis based on consistent 
improvement in the T25FW. The proportion of T25FW 
responders was significantly higher in the fampridine group 
(78/224 or 35%) than in the placebo group (6/72 or 8%), 
indicating that fampridine was associated with an improve-
ment in walking ability among persons with MS. The com-
bination of exercise training and fampradine potentially has 
clinically meaningful, and perhaps synergistic, effects on 
mobility outcomes. There are two potential mechanisms 
for such augmentation. One is that exercise training and 
fampradine likely work through different mechanisms for 
improving mobility outcomes. The second is that fampra-
dine might improve one’s capacity for engaging in exercise 
training. This might allow for undertaking a greater exercise 
training stimulus and perhaps experiencing larger adapta-
tions, including improvements in physiological functioning 
and reductions in walking impairment.
One additional application of exercise training might be 
for better tolerating the side effects of pharmacological agents 
commonly used in modifying the course of MS. Indeed, 
interferon-beta medications are first-line treatments for MS, 
with increasing evidence for short-term and long-term effects 
on the progression of mobility disability.38 One factor that 
undermines the long-term administration of such disease 
modifying agents is the occurrence of side effects such as 
flu-like symptoms and, in some cases, fatigue. To that end, 
research might consider the addition of exercise training as 
an approach for minimizing the side effects of interferon-
beta medications, particularly fatigue.31 This would ideally 
allow for improved tolerance, adherence, and long-term 
outcomes.
The final consideration involves increased basic science 
research that examines effects of exercise training on MS 
using experimental autoimmune encephalomyelitis (EAE) as 
a model of MS. Indeed, researchers have recently provided 
exciting results regarding the effects of voluntary wheel run-
ning on clinical, synaptic, and neuropathological outcomes 
using EAE as a model of MS.27 This research suggests that 
lifestyle physical activity might play a central role in the 
clinical course of MS, and this basic science approach might 
ultimately identify that changes in the CNS account for 
improved ambulatory function with exercise training.
Conclusion
The adoption of exercise training and physical activity as 
behavioral influences of walking impairment in persons 
with MS might have considerable significance for public 
health and clinical care. Disease modifying agents have 
limited efficacy in slowing eventual progression of mobil-
ity disability over time,44,45 and researchers have argued for 
the identification of alternative approaches that retard the 
progression of mobility disability in persons with MS.9,10 
We argue that exercise training and physical activity behavior 
change interventions might represent powerful, alternative 
approaches for mitigating the progression of walking impair-
ment by improving physiological functioning in persons with 
MS. An alternative perspective is that the effect of exercise 
training and physical activity on walking might occur through 
synaptogenesis, nerve growth factors, or symptom manage-
ment. Nevertheless, the relevance for clinicians and therapists 
who care for MS patients is that exercise training and physi-
cal activity behavior change interventions can be integrated 
within rehabilitation regimens for possibly preventing the 
onset and progression of mobility disability. This is consistent 
with the recommendation by some experts that rehabilitation Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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is the only practical means of improving function, and 
perhaps attenuating the progression of walking impairment, 
in persons with MS.46 Future research on exercise training 
and physical activity has the potential to significantly advance 
the management of progressive walking impairment in MS, 
and this effect might be further examined in the context of 
disease modifying agents that affect walking ability and/or 
disease progression.
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